Feature

Cost gap widens between brand-name, generic drugs


 

The average cost of a brand-name drug was 18.6 times higher than its generic equivalent in 2017, and the size of that gap has more than tripled since 2013, according to a report from the AARP Public Policy Institute.

Average annual cost of therapy: Generics vs. brand-name drugs

In 2017, the average retail cost of 260 generic drugs widely used by older adults for chronic conditions was $365 for a year of therapy, compared with $6,798 for brand-name drugs. In 2013, that same year of therapy with an average brand-name drug ($4,308) was only 5.7 times more expensive than the generic ($751), the AARP wrote in the report, produced in collaboration with the PRIME Institute at the University of Minnesota, Minneapolis.

“Generics account for nearly 9 out of every 10 prescriptions filled in the U.S. but represent less than a quarter of the country’s drug spending. These results highlight the importance of eliminating anticompetitive behavior by brand-name drug companies so that we get more lower-priced generic drugs on the market,” Debra Whitman, executive vice president and chief public policy officer at AARP, said in a written statement.

The average retail cost of a larger group of 390 generic drugs used by older adults fell by 9.3% from 2016 to 2017, compared with an increase of 8.4% for a group of 267 brand-name prescription drugs. Over that same time, the general inflation rate rose by 2.1%, the AARP noted.

The AARP’s annual Rx Price Watch Report is based on data from the Truven Health MarketScan research databases.

Recommended Reading

DoJ refuses to challenge Texas ACA ruling
MDedge ObGyn
Montana named ‘best state to practice medicine’ in 2019
MDedge ObGyn
FDA chief calls for release of all data tracking problems with medical devices
MDedge ObGyn
Who’s increasing health care costs? Not us!
MDedge ObGyn
Following pelvic floor surgery, patients value functional goals
MDedge ObGyn
Malpractice: More lawsuits does not equal more relocations
MDedge ObGyn
ONC’s Dr. Rucker: Era of provider-controlled data is over
MDedge ObGyn
MedPAC to begin work on Part D redesign
MDedge ObGyn
Proportion of women speaking at medical conferences rises over decade
MDedge ObGyn
As Sanders officially revives Medicare-for-all, Plan B for Democrats gains traction
MDedge ObGyn